AGES

ISPE Announces Health Authority Representatives from Australia, Austria, Germany, Switzerland, and the US as Featured Speakers at the 2024 ISPE Aseptic Conference

Retrieved on: 
Thursday, February 22, 2024
Competent authority, Asepsis, TGA, FDA, ISPE, US FDA, AGES, International Society, Medication, Pharmaceutical industry, Conference, Health, RP, Therapeutic Goods Administration, Patient, Knowledge

NORTH BETHESDA, Md., Feb. 22, 2024 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) has announced representative participation from health authorities around the world at the 2024 ISPE Aseptic Conference. Featured speakers include representatives from the Austrian Agency for Health and Food Safety (AGES/Austria), Regierungspraesidium (RP) Tübingen in Germany, Swissmedic in Switzerland, the Therapeutic Goods Administration (TGA) in Australia, and the United States Food and Drug Administration (US FDA).

Key Points: 
  • The 2024 ISPE Aseptic Conference will take place 12-13 March 2024 in Vienna, Austria, and virtually.
  • NORTH BETHESDA, Md., Feb. 22, 2024 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering ( ISPE ) has announced representative participation from health authorities around the world at the 2024 ISPE Aseptic Conference .
  • Esteemed representatives from these national regulatory agencies will discuss current issues in aseptic processing from a technical perspective.
  • "I am very honored to be one of the keynote speakers at the 2024 ISPE Aseptic Conference in Vienna.

Vetter’s European Clinical Site Receives Permanent Manufacturer’s Authorization

Retrieved on: 
Thursday, November 9, 2023
Packaging, Health, Manufacturing, Clinical Trials, Pharmaceutical, Biotechnology, Documentation, II, Quality control, CDMO, Multimedia, Integrated Child Development Services, Patient, AGES

Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria .

Key Points: 
  • Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria .
  • Operational for nearly two years, the responsible national regulatory authority, the Austrian Agency for Health and Food Safety (AGES) again inspected the site for issuance of a permanent Manufacturer’s Authorization.
  • View the full release here: https://www.businesswire.com/news/home/20231109837386/en/
    High quality standards in aseptic production at Vetter’s clinical site in Vorarlberg, Austria.
  • © Vetter Pharma International GmbH: High quality standards in aseptic production at Vetter’s clinical site in Vorarlberg, Austria.

EQS-News: invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

Retrieved on: 
Tuesday, September 5, 2023
GMP, Index, Progression-free survival, Neoplasm, FFG, Biotechnology, Clinical trial, Cancer, Lung cancer, Austrian Research Promotion Agency, Head, Medical school, Epic, Biomarker, Neck, PFS, Gesellschaft mit beschränkter Haftung, Small RNA, Science, Protein, AGES, Patient, Medical University of Innsbruck, Immune system, TME, MMD, MTD, ORR, Safety, Pharmaceutical industry, Medical imaging, Vaccine

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

Key Points: 
  • invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
    The issuer is solely responsible for the content of this announcement.
  • invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
    Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started;
    invIOs awarded up to 45% funding of trial costs by Austrian Research Promotion Agency (FFG) to support Phase 1b RP2D trial;
    invIOs recently also awarded grant funding to advance novel CAR-T cell therapy INV451 against lung cancer with Medical University of Innsbruck.
  • PALINDROM is a multi-center trial taking place in Austria with two GMP-compliant manufacturing sites in Vienna and Linz.
  • As part of the Austrian Life Sciences Programme 2023 initiative, the Austrian Research Promotion Agency (FFG) has awarded invIOs funding to support the PALINDROM study.

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

Retrieved on: 
Tuesday, September 5, 2023
GMP, Index, Progression-free survival, Neoplasm, FFG, Biotechnology, Clinical trial, Cancer, Lung cancer, Austrian Research Promotion Agency, Head, Medical school, Epic, Biomarker, Neck, PFS, Gesellschaft mit beschränkter Haftung, Small RNA, Science, Protein, AGES, Patient, Medical University of Innsbruck, Immune system, TME, MMD, MTD, ORR, Safety, Pharmaceutical industry, Medical imaging, Vaccine

VIENNA, Austria, Sept. 05, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that it has started patient recruitment for a Phase 1b trial of its novel autologous cell therapy, APN401, in patients with solid tumors, and has successfully secured grant funding.

Key Points: 
  • VIENNA, Austria, Sept. 05, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that it has started patient recruitment for a Phase 1b trial of its novel autologous cell therapy, APN401, in patients with solid tumors, and has successfully secured grant funding.
  • PALINDROM is a multi-center trial taking place in Austria with two GMP-compliant manufacturing sites in Vienna and Linz.
  • As part of the Austrian Life Sciences Programme 2023 initiative, the Austrian Research Promotion Agency (FFG) has awarded invIOs funding to support the PALINDROM study.
  • “I am delighted that the Austrian government is supporting our latest clinical trial using the EPiC cell therapy platform to develop an innovative and potentially game-changing approach to treating solid tumors,” said Peter Llewellyn-Davies, CEO of invIOs.

Vetter’s Newest Clinical Manufacturing Site Successfully Completed Its First Customer Fills

Retrieved on: 
Tuesday, June 28, 2022
Biotechnology, Pharmaceutical, Health, Biotechnology, CGMP, New business development, AGES, Syringe, CDMO, Compliance, Contract, Social responsibility, Solution, Drug development, Multimedia, Fine chemical, Rankweil

With the realization of the first successful customer fills, Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria.

Key Points: 
  • With the realization of the first successful customer fills, Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria.
  • Within one year of its purchase, the site was adapted and integrated to meet Vetters high quality standards.
  • We have been highly focused on achieving the strategic integration of the site, said Dr. Martin Schwab, Site Head Austria.
  • Vetter services range from early stage development support including clinical manufacturing , to commercial supply and numerous packaging solutions for vials, syringes and cartridges.

Vetter’s New Clinical Manufacturing Site Now Officially Authorized

Retrieved on: 
Wednesday, January 19, 2022
Health, Manufacturing, Research, Other Manufacturing, Science, Pharmaceutical, Biotechnology, Patient, Biotechnology, CDMO, Social responsibility, Contract, Quality assurance, GMP, Quality control, CGMP, Multimedia, AGES, Compliance, II, Senior, Patient safety, Syringe, Pharmaceutical industry, Fine chemical, Rankweil, Vetter

Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has received the manufacturing authorization for its new site in Rankweil, Austria.

Key Points: 
  • Vetter , a leading global Contract Development and Manufacturing Organization (CDMO), has received the manufacturing authorization for its new site in Rankweil, Austria.
  • View the full release here: https://www.businesswire.com/news/home/20220119005682/en/
    Manufacturing of prefilled vial systems at Vetter (Photo: Business Wire)
    Vetter Development Service Rankweil represents the companys European counterpart to its existing clinical manufacturing site near Chicago.
  • With the new site further expanding its international presence , Vetter is responding to the growing global demand for fill & finish services.
  • The successfully completed cGMP inspection by AGES enables the new clinical manufacturing facility in Rankweil to officially start operations and to realize customer projects in the clinical development phase on their way to approval.

Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award, and Looks Back on a Stable Year Under Ongoing Pandemic Circumstances

Retrieved on: 
Tuesday, December 7, 2021
Biotechnology, Manufacturing, Health, Pharmaceutical, Packaging, Motivation, Contract, Biotechnology, CO2, Quality control, Quality of life, Coronavirus, Syringe, Frost & Sullivan, Patient, Social responsibility, AGES, Multimedia, Achievement, Frost, CDMO, Interview, Compliance, Video game, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20211207005732/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211207005732/en/
    Vetter Wins Frost & Sullivans 2021 Global Customer Value Leadership Award (Graphic: Business Wire)
    The award decision process involved three major steps: first, Frost & Sullivan examined service providers from the global pharmaceutical and biotech industry and their focus on both business and customer impact.
  • The examination incorporates ten criteria including financial performance, operational efficiency, growth potential, price/performance value as well as customer service experience.
  • Third, a nomination compendium was created that contains all the necessary substantiation and justification and was thoroughly reviewed by Frost & Sullivans Best Practices Recognition committee.
  • Vetter was recognized for providing high customer value, in particular, the companys best practices in collaboration with global customers.

Advisory Group Equity Services Announces Official Launch of Flagship Investment Banking Division, Trust Capital Markets, to Serve Growth Stage & Middle-Market Companies

Retrieved on: 
Tuesday, August 17, 2021
Trust, Growth, Life, Investment banking, Leadership, Disability, Insurance, AGES, Techniques d'Avant Garde, RIA, High-net-worth individual, Solution, CEO, Sale, Housing, TAG, Artificial intelligence, Professional, TCM, Financial services, Security (finance), Financial adviser

Trust Capital Markets is led by Jeffery Morfit, appointed as the Head of Investment Banking, to execute AGES's vision of growth and performance in investment banking.

Key Points: 
  • Trust Capital Markets is led by Jeffery Morfit, appointed as the Head of Investment Banking, to execute AGES's vision of growth and performance in investment banking.
  • Advisory Group Equity Services Ltd., led by President and CEO, William McCance, is excited to be launching the new banking division.
  • About Advisory Group Equity Services Ltd.: Advisory Group Equity Services, LTD. ("AGES", www.agesbrokerage.com ) is a full-service broker dealer and member FINRA/SIPC/MSRB founded in 1984.
  • TAG Group, Inc. maintains three separate and distinct operating units Trust Advisory Group, Advisory Group Equity Services, and Estate Insurance Services.